{"entity":{"id":"richard-stone","kind":"person","name":"Richard M. Stone","aka":[],"tldr":"Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML.","summary":"Richard Stone was principal investigator of RATIFY (CALGB 10603), the international trial showing midostaurin added to standard chemotherapy improves survival in FLT3-mutant AML, the first new approval in AML induction in 40 years and the first targeted therapy in the disease. He chaired the Alliance leukaemia committee and has led trials across AML, including gemtuzumab and quizartinib studies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RM%5BAuthor%5D%20midostaurin%20RATIFY"}],"tags":["aml","flt3","cooperative-group"],"related":[],"cancers":["aml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["flt3"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["ratify","quantum-first"],"people":[],"bottlenecks":[],"keyPapers":["paper-quantum-first-quizartinib-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Staff and Director of Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Acute myeloid leukaemia","FLT3 inhibitors","Cooperative-group trials","Leukaemia therapeutics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RM%5BAuthor%5D%20midostaurin%20RATIFY"}],"papers":[{"title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation (RATIFY)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1614359"},{"title":"Acute myeloid leukemia","journal":"NEJM","year":2015,"doi":"10.1056/NEJMra1406184"},{"title":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=QuANTUM-First%20quizartinib%20FLT3-ITD%20Erba%20Lancet%202023"}],"orcid":"0000-0002-7526-2633"},"route":"/people/richard-stone/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"trial":[{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/"},{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/"}],"paper":[{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/"}]}}